The company remains entirely pre-revenue, with zero reported sales over the last ten quarters and quarterly R&D costs reaching $1.5 million as of 2026Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 12K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | -12K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 17.02M | 11.59M | 12.03M | 1.99M | 13.59M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 9.89M | 6.86M | 5.25M | 1.25M | 13.59M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 7.14M | 4.72M | 2.23M | 745K | 4.07K |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | -12K | 0 | 4.56M | 0 | 0 |
| Operating Income | -17.03M | -11.59M | -12.03M | -1.99M | -13.59M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | -47% | 3.67% | -504.52% | 85.36% | - |
| EBITDA | -17.02M | -11.4M | -11.95M | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -49.25% | 4.55% | - | - | - |
| D&A (Non-Cash Add-back) | 12K | 183K | 81K | 1.99M | 13.59M |
| EBIT | -17.03M | -11.23M | -15.35M | -1.99M | -13.59M |
| Net Interest Income | 319K | 178K | 48K | 0 | -218.09K |
| Interest Income | 319K | 354K | 127K | 0 | 0 |
| Interest Expense | 0 | 176K | 79K | 0 | 218.09K |
| Other Income/Expense | 319K | 178K | -3.4M | 0 | 265.56K |
| Pretax Income | -16.71M | -11.41M | -15.43M | -1.99M | -13.33M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -16.71M | -11.41M | -15.43M | -1.99M | -13.33M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | -46.49% | 26.03% | -675.18% | 85.07% | - |
| Net Income (Continuing) | -16.71M | -11.41M | -15.43M | -1.99M | -13.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -48.72 | -135.66 | -442.89 | -2.31 | -14.91 |
| EPS Growth % | 64.09% | 69.37% | -19072.73% | 84.51% | - |
| EPS (Basic) | -48.72 | -135.66 | -443.10 | -2.31 | -14.91 |
| Diluted Shares Outstanding | 343.65K | 84.09K | 34.82K | 894.95K | 894.95K |
| Basic Shares Outstanding | 343.65K | 84.09K | 34.81K | 894.95K | 894.95K |
| Dividend Payout Ratio | - | - | - | - | - |
Clinical trial funding exhaustion
As indicated by the company's financial statements, Autonomix Medical remains entirely pre-revenue, with zero reported sales across the last ten quarters, underscoring that the firm is currently in a development-stage phase where growth metrics are not yet applicable to evaluate commercial traction or market adoption.
The absence of revenue confirms that the company is currently focused exclusively on clinical validation rather than commercialization. Investors should monitor the transition from R&D to potential revenue generation, as the current lack of top-line data makes traditional growth analysis impossible.
According to recent SEC filings, R&D expenditures have trended upward, reaching $1.5 million in 2026Q4, which reflects the intensifying costs associated with clinical trial site management and regulatory navigation as the company attempts to validate its proprietary microchip-enabled sensing technology in human environments.
The firm's cost structure is heavily skewed toward R&D, which is typical for a medical device company at this stage of development. This high fixed-cost burden suggests that the company must achieve significant clinical milestones to justify the ongoing capital expenditure.
Based on reported figures, the company's net loss of $2.7 million in 2026Q4 is heavily influenced by non-operating expenses and stock-based compensation, which complicates the assessment of core operational efficiency and the true underlying burn rate of the business during this critical clinical development period.
The volatility in EPS, ranging from -2.94 to -51.87, suggests that accounting adjustments and share-based compensation are creating significant noise in the bottom line. Analysts should focus on cash burn rather than net income to understand the company's actual financial health.
As reported in financial statements, the company maintains a limited cash position of approximately $7 million, which, when measured against the quarterly operating losses, suggests a high probability of future dilutive financing or strategic partnerships being required to sustain operations through the next clinical readout.
The current burn rate appears unsustainable without a capital infusion, placing the company in a vulnerable position regarding its regulatory timeline. Any delay in clinical enrollment could force management to seek capital under unfavorable market conditions, further diluting existing shareholders.
Quick answers to the most common questions about buying AMIX stock.
For fiscal year 2026, Autonomix Medical, Inc. (AMIX) reported total revenue of $0.0M.
Autonomix Medical, Inc. (AMIX) reported a net loss of $16.7M for the fiscal year ending 2026.